Disc Medicine Lays Off 20% Post-FDA Rejection
March 4, 2026
Disc Medicine cuts ~20% (~50 employees) after FDA rejection of bitopertin for congenital erythropoietic porphyria, halting programme and refocusing pipeline.
Amgen–Disc Medicine $618m Cancer Target Deal
January 8, 2026
Amgen partners Disc Medicine in $618m collaboration for an undisclosed cancer target using Disc’s erythroferrone and iron regulation expertise.